BioTuesdays

Category - Markets

Viking Therapeutics Logo
Markets

Feltl starts Viking Therapeutics at strong buy

Feltl & Co. has launched coverage of Viking Therapeutics (NASDAQ:VKTX) with a “strong buy” rating and price target of $17.50. The stock closed at $6.90 on Wednesday. “We anticipate the company executing on multiple...

October 15, 2015
Prima BioMed
Markets

HCW starts Prima BioMed at buy

H.C. Wainwright has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and $3 price target. The stock closed at $1.22 on Tuesday. Australia-based Prima is developing novel checkpoint modulators (CPMs)...

October 14, 2015
Titan Pharmaceuticals Logo
Markets

Titan Pharma to uplist to NASDAQ

Titan Pharmaceuticals (OTCQB:TTNPD) has received approval to list its common stock on the NASDAQ Capital Market, effective at the opening on Monday, Oct.12, under the symbol TTNP. “Uplisting to the NASDAQ Capital Market...

October 8, 2015
Immune Pharmaceuticals
Markets

Roth starts Immune Pharma at buy

Roth Capital Partners has initiated coverage of Immune Pharmaceuticals (NASDAQ:IMNP) with a “buy” rating and $6 price target. The stock closed at $1.21 on Wednesday. Immune is developing bertilimumab in combating...

October 8, 2015
novadaq
Markets

Wedbush starts Novadaq at outperform

Wedbush Securities has initiated coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with an “outperform” rating and 12-month price target of $15. The stock closed at $11.29 on Wednesday. Novadaq’s flagship SPY...

October 7, 2015
Evoke Pharma
Markets

Rodman starts Evoke Pharma at buy

Rodman & Renshaw has initiated coverage of Evoke Pharma (NASDAQ:EVOK) with a “buy” rating and $27 price target. The stock closed at $2.91 on Wednesday. Evoke is currently focused on advancing an intranasal...

October 1, 2015
oramed
Markets

Rodman starts Oramed at buy

Rodman & Renshaw has launched coverage of Oramed Pharmaceuticals (NASDAQ:ORMD) with a “buy” rating and $24 price target. The stock closed at $5.47 on Wednesday. “Oramed constitutes a differentiated take on diabetes...

October 1, 2015
ANI Pharmaceuticals
Markets

Roth upgrades ANI Pharma to buy

Roth Capital Partners has upgraded ANI Pharmaceuticals (NASDAQ:ANIP) to ”buy” from “neutral” but lowered its price target to $60 from $67. The stock closed at $43.21 on Friday. “We are upgrading shares of ANI...

September 28, 2015
Conatus
Markets

HCW starts Conatus Pharma at buy

H.C. Wainwright has initiated coverage of Conatus Pharmaceuticals (NASDAQ:CNAT) with a “buy” rating and $15 price target, saying that the company’s emricasan drug candidate has disease-modifying potential across the...

September 22, 2015
Can-Fite
Markets

Can-Fite in $9-million registered direct offering

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has entered into definitive agreements with institutional investors to raise $9-million through the sale of 2,068,966 American Depository Shares (ADS) at a price of $4.35...

September 21, 2015